Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Great Basin Scientific, a privately held life sciences company developing point-of-care molecular diagnostic solutions, has closed a $3.9 million financing round. New and returning investors participated in the funding for this round.
Subscribe to our email newsletter
According to Great Basin Scientific, the new round of financing will fund the company through the spring of 2009 as it completes the design of its rapid molecular diagnostic testing platform and brings a methicillin-resistant Staphylococcus aureus test into clinical trials.
Ryan Ashton, president and CEO of Great Basin Scientific, said: “This financing coincides with an exciting time for our company as we begin to develop important technology that will bring rapid disease diagnosis nearer to the patient to improve clinical outcomes and reduce treatment cost. This commitment by our investors shows a strong indication of confidence in our innovation, use of technology, strategy and leadership team.”